Founded in Japan in 1968, Sysmex Corporation delivers total solutions in the field of clinical laboratory testing, including haematology and urinalysis. In the field of haematology, Sysmex is the global market leader, occupying the number one share of the worldwide market. It is also number one supplier of haemostasis instrumentation worldwide. Sysmex currently has more than 60 Group companies in over 40 countries around the world. Sysmex products are used by medical institutions in more than 190 countries. Sysmex Asia Pacific Pte Ltd is a subsidiary of Sysmex Corporation. Set up as a Representative Office in 1994, it was subsequently established as Sysmex Singapore Pte Ltd in 1998 and eventually became known as Sysmex Asia Pacific Pte Ltd in October 2005. Located at the centre of regional market operations, Singapore is Sysmex’s headquarters in the Asia Pacific region. Sysmex Affiliates in Asia Pacific are in India, Thailand, Malaysia, Indonesia, New Zealand, Australia, Philippines and Vietnam. Sysmex also has a representative office in Myanmar. In Asia Pacific, Sysmex is a market leader in the delivery and implementation of clinical IVD and health IT products and services for clinical laboratories, hospitals and healthcare organisations. Its products and solutions continuously improve patient clinical services and efficiency, translating into cost effective delivery of better patient care. For Research and Development, Sysmex possesses specialised technologies spanning a broad range of fields, including electronics, mechanics, biology, chemistry and information processing. The integration of these specialised technologies has created core diagnostic technologies for Sysmex. Sysmex is constantly pursing the creation of new core technologies with the ultimate aim to develop new diagnostics that will support the prevention, early detection and early treatment of disease. The company is already in the midst of creating new testing methodologies that will lead to a better understanding of patients’ pathological conditions and diseases, and will optimise their treatment and improve their quality of life.